Clinical trials: Plasma Cell Tumor
Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them.
- Trial name
- NCT01429025
- Testing
- rituximab, bendamustine, lenalidomide
- Where
- 17 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
This phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a genetic change called PTEN mutation or deletion.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439149
- Testing
- PI3K-beta Inhibitor GSK2636771
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Multiple Myeloma
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
This phase I/II trial tests the safety, side effects, and best dose of iberdomide and how well it works in combination with daratumumab, elotuzumab, and dexamethasone in treating patients with multiple myeloma that has come back…
- Trial name
- NCT06785415
- Testing
- Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance if they are MRD-positive after Autologous Stem Cell Transplant (ASCT)
- Trial name
- HEME-18 (NCT05344833)
- Testing
- Isatuximab, Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Illinois Chicago
Leukemia, Hodgkin Lymphoma
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
The goals of the study are (Phase I) to determine the appropriate dose for Clofarabine with Busulfan as a full-intensity conditioning (Clo/BU4 regimen) prior to transplant and then (Phase II) to investigate the safety and…
- Conditions
- Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma
- Trial name
- NCT00556452
- Testing
- Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant, Total Lymphoid Irradiation
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Michigan Rogel Cancer Center
Multiple Myeloma
Bortezomib With Melphalan and Prednisone for Multiple Myeloma
The purpose of this study is to assess the efficacy of bortezomib in combination with melphalan and prednisone to achieve complete responses for patients with previously untreated multiple myeloma compared to an historical…
- Trial name
- MVP (NCT00734149)
- Testing
- Bortezomib, Melphalan, Prednisone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Duke University
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
This randomized clinical trial studies standard GVHD prophylaxis with tacrolimus and methotrexate compared to tacrolimus, mycophenolate mofetil and a reduced-dose methotrexate in patients with hematologic malignancies undergoing…
- Conditions
- Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia
- Trial name
- NCT01951885
- Testing
- tacrolimus, methotrexate, Mycophenolate mofetil
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Case Comprehensive Cancer Center
Refractory Multiple Myeloma, Multiple Myeloma in Relapse
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.
- Conditions
- Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
- Trial name
- NCT03702725
- Testing
- Ibrutinib, Lenalidomide, Dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Alliance Foundation Trials, LLC.
Myeloma
Phase II Study of Simvastatin for Relapsed/Refractory Myeloma
The purpose of this study test the hypothesis that the combination of simvastatin and zoledronic acid (for reversal of drug resistance), with bortezomib, high-dose methylprednisolone and bendamustine on a day 1,8 schedule (to…
- Trial name
- NCT01332617
- Testing
- Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.
- Sponsor
- University of Louisville
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00305812
- Testing
- dexamethasone, lenalidomide, melphalan
- Where
- 14 sites in Canada
- Volunteers
- 51 people
- Sponsor
- NCIC Clinical Trials Group
Hematologic Malignancy, Large B-cell Lymphoma
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
The study is designed to examine the feasibility and safety of collecting autologous hematopoietic stem cells (HSCs) to be combined with CAR T-cell therapy for patients with relapsed/refractory (r/r) hematological disease.
- Conditions
- Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT05887167
- Testing
- autologous hematopoietic stem cells added to planned CAR T
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Joshua Sasine, MD, PhD
Multiple Myeloma
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
Background: Autologous hematopoietic stem cell transplantation(ASCT) is an important part treatment for patients with multiple myeloma.
- Trial name
- NCT05855122
- Testing
- Tocilizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
There is a high unmet medical need for an anti-myeloma therapy for RRMM patients previously treated with Lenalidomide and Bortezomib, due to poor prognosis.
- Trial name
- NCT02555839
- Testing
- Pomalidomide, Dexamethasone, Bortezomib
- Where
- 13 sites in Austria
- Volunteers
- 127 people
- Sponsor
- Celgene
Solitary Bone Plasmacytoma, Plasmacytoma of Bone
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA/CD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with…
- Conditions
- Solitary Bone Plasmacytoma, Plasmacytoma of Bone, Plasma Cell Disorders
- Trial name
- NCT07115667
- Testing
- BCMA/CD3 bispecific antibody (CM336)
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL)
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
- Trial name
- RUBIN (NCT06043011)
- Testing
- Routine care as per site standard.
- Where
- Germany
- Volunteers
- 2,950 people
- Sponsor
- iOMEDICO AG
Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to…
- Trial name
- NCT07336472
- Testing
- IBI3003
- Where
- 6 sites in United States
- Volunteers
- 360 people
- Sponsor
- Fortvita Biologics (USA)Inc.
Amyloid, Cardiac Amyloidosis
Amyloidosis Incidence in High-Risk Cardiac Device Patients
This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation.
- Conditions
- Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis
- Trial name
- NCT06186167
- Testing
- Chest Wall Fat Tissue Collection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Midwest Heart & Vascular Specialists
Multiple Myeloma
A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine if there is an improvement in progression-free survival (length of time during and after treatment in which a patient is living with a disease that does not get worse) when siltuximab is…
- Trial name
- NCT01266811
- Testing
- Siltuximab, Velcade and dexamethasone
- Where
- 48 sites in United States, Australia and 12 more
- Sponsor
- Centocor, Inc.
Newly Diagnosed Multiple Myeloma
Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)
This is a phase II, multicenter, open-label study to evaluate the safety and efficacy of MLN9708 in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed multiple myeloma.
- Trial name
- IFM2013-06 (NCT01936532)
- Testing
- MLN9708, Lenalidomide, Dexamethasone
- Where
- 10 sites in France
- Volunteers
- 42 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib after an autologous peripheral blood stem cell transplant may stop the growth of any cancer cells…
- Trial name
- NCT00288028
- Testing
- bortezomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.